When patients are given VA-ECMO support therapy, ECMO shares the workload done by the heart, resulting in the alleviation of cardiac failure symptoms, a decrease in the release of inflammatory factors, and a gradual decrease in Gal-3 levels. The gene discussed is LGALS3; the disease is heart failure.